The oncogene ERG: A key factor in prostate cancer

Oncogene

Volumn 35, Issue 4, 2016, Pages 403-414

  Adamo, P ^a   Ladomery, M R ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR ERG; ANDROGEN RECEPTOR; AR PROTEIN, HUMAN; ERG PROTEIN, HUMAN; ONCOPROTEIN; TMPRSS2-ERG FUSION PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR MARKER;

ALTERNATIVE RNA SPLICING; CANCER PROGNOSIS; ERG GENE; GENE FUSION; GENE INDUCTION; GENE TARGETING; HUMAN; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN DNA BINDING; REVIEW; SIGNAL TRANSDUCTION; TMPRRSS2 GENE; TRANSCRIPTION REGULATION; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATIC NEOPLASMS;

ALTERNATIVE SPLICING; BIOMARKERS, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; ONCOGENE PROTEINS, FUSION; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANS-ACTIVATORS;

EID: 84955655198     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.109     Document Type: Review

References (205)

1. Leprince D, Gegonne A, Coll J, De Taisne C, Schneeberger A, Lagrou C et al. A putative second cell-derived oncogene of the avian leukaemia retrovirus E26. Nature 1983; 306: 395-397.
2. Nunn MF, Seeburg PH, Moscovici C, Duesberg PH. Tripartite structure of the avian erythroblastosis virus E26 transforming gene. Nature 1983; 306: 391-395.
3. Rao VN, Papas TS, Reddy E. ERG, a human ets-related gene on chromosome 21: alternative splicing, polyadenylation, and translation. Science 1987; 237: 635-639.
4. Boulukos K, Pognonec P, Rabault B, Begue A, Ghysdael J. Definition of an ETS1 protein domain required for nuclear localization in cells and DNA-binding activity in vitro. Mol Cell Biol 1989; 9: 5718-5721.
5. Meadows SM, Myers CT, Krieg PA. Regulation of endothelial cell development by ETS transcription factors. Sem Cell Dev Biol 2011; 22: 976-984.
6. Watson DK, McWilliams MJ, Lapis P, Lautenberger JA, Schweinfest CW, Papas TS. Mammalian ETS-1 and ETS-2 genes encode highly conserved proteins. Proc Natl Acad Sci USA 1988; 85: 7862-7866.
7. Larroux C, Fahey B, Liubicich D, Hinman VF, Gauthier M, Gongora M et al. Developmental expression of transcription factor genes in a demosponge: insights into the origin of metazoan multicellularity. Evol Dev 2006; 8: 150-173.
8. Garrett-Sinha LA. Review of ETS1 structure, function, and roles in immunity. Cell Mol Life Sci 2013; 70: 3375-3390.
9. Watson D, McWilliams-Smith M, Nunn M, Duesberg P, O'Brien S, Papas T. The ets sequence from the transforming gene of avian erythroblastosis virus, E26, has unique domains on human chromosomes 11 and 21: both loci are transcriptionally active. Proc Natl Acad Sci USA 1985; 82: 7294-7298.
10. Reddy E, Rao V. ERG, an ETS-related gene, codes for sequence-specific transcriptional activators. Oncogene 1991; 6: 2285-2289.
11. Heo SH, Choi YJ, Ryoo HM, Cho JY. Expression profiling of ETS and MMP factors in VEGF-activated endothelial cells: role of MMP-10 in VEGF-induced angiogenesis. J Cell Physiol 2010; 224: 734-742.
12. Gutierrez-Hartmann A, Duval DL, Bradford AP. ETS transcription factors in endocrine systems. Trends Endocrinol Metab 2007; 18: 150-158.
13. Nikolova-Krstevski V, Yuan L, Le Bras A, Vijayaraj P, Kondo M, Gebauer I et al. ERG is required for the differentiation of embryonic stem cells along the endothelial lineage. BMC Dev Biol 2009; 9: 72.
14. Yuan L, Sacharidou A, Stratman AN, Le Bras A, Zwiers PJ, Spokes K et al. RhoJ is an endothelial cell-restricted Rho GTPase that mediates vascular morphogenesis and is regulated by the transcription factor ERG. Blood 2011; 118: 1145-1153.
15. Birdsey GM, Dryden NH, Amsellem V, Gebhardt F, Sahnan K, Haskard DO et al. Transcription factor ERG regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood 2008; 111: 3498-3506.
16. McLaughlin F, Ludbrook VJ, Cox J, von Carlowitz I, Brown S, Randi AM. Combined genomic and antisense analysis reveals that the transcription factor ERG is implicated in endothelial cell differentiation. Blood 2001; 98: 3332-3339.
17. Loughran SJ, Kruse EA, Hacking DF, de Graaf CA, Hyland CD, Willson TA et al. The transcription factor ERG is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells. Nat Immunol 2008; 9: 810-819.
18. Bosco A, Bureau C, Affaticati P, Gaspar P, Bally-Cuif L, Lillesaar C. Development of hypothalamic serotoninergic neurons requires Fgf signalling via the ETS-domain transcription factor Etv5b. Development 2013; 140: 372-384.
19. Birdsey GM, Dryden NH, Shah AV, Hannah R, Hall MD, Haskard DO et al. The transcription factor ERG regulates expression of histone deacetylase 6 and multiple pathways involved in endothelial cell migration and angiogenesis. Blood 2012; 119: 894-903.
20. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009; 41: 619-624.
21. Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 2008; 105: 2105-2110.
22. Sperone A, Dryden N, Birdsey G, Madden LE, Evans P, Mason JC et al. The transcription factor ERG represses ICAM-1 expression and vascular inflammation. Atherosclerosis 2010; 213: e17.
23. Yuan L, Le Bras A, Sacharidou A, Itagaki K, Zhan Y, Kondo M et al. ETS-related gene (ERG) controls endothelial cell permeability via transcriptional regulation of the claudin 5 (CLDN5) gene. J Biol Chem 2012; 287: 6582-6591.
24. Reddy E, Rao VN, Papas TS. The ERG gene: a human gene related to the ets oncogene. Proc Natl Acad Sci 1987; 84: 6131-6135.
25. Lautenberger J, Burdett L, Gunnell M, Qi S, Watson D, O'Brien S et al. Genomic dispersal of the ETS gene family during metazoan evolution. Oncogene 1992; 7: 1713-1719.
26. Vijayaraj P, Le Bras A, Mitchell N, Kondo M, Juliao S, Wasserman M et al. ERG is a crucial regulator of endocardial-mesenchymal transformation during cardiac valve morphogenesis. Development 2012; 139: 3973-3985.
27. Maroulakou IG, Bowe DB. Expression and function of ETS transcription factors in mammalian development: a regulatory network. Oncogene 2000; 19: 6432-6442.
28. Mohamed AA, Tan S-H, Mikhalkevich N, Ponniah S, Vasioukhin V, Bieberich CJ et al. ETS family protein, ERG expression in developing and adult mouse tissues by a highly specific monoclonal antibody. J Cancer 2010; 1: 197.
29. Ng AP, Loughran SJ, Metcalf D, Hyland CD, de Graaf CA, Hu Y et al. ERG is required for self-renewal of hematopoietic stem cells during stress hematopoiesis in mice. Blood 2011; 118: 2454-2461.
30. Birdsey GM, Shah AV, Dufton N, Reynolds LE, Almagro LO, Yang Y et al. The endothelial transcription factor ERG promotes vascular stability and growth through Wnt/â-catenin signaling. Dev Cell 2015; 32: 82-96.
31. Lathen C, Zhang Y, Chow J, Singh M, Lin G, Nigam V et al. ERG-APLNR axis controls pulmonary venule endothelial proliferation in pulmonary veno-occlusive disease. Circulation 2014; 130: 1179-1191.
32. Vlaeminck-Guillem V, Carrere S, Dewitte F, Stehelin D, Desbiens X, Duterque-Coquillaud M. The ETS family member ERG gene is expressed in mesodermal tissues and neural crests at fundamental steps during mouse embryogenesis. Mech Dev 2000; 91: 331-335.
33. Schachterle W, Rojas A, Xu S-M, Black BL. ETS-dependent regulation of a distal Gata4 cardiac enhancer. Dev Biol 2012; 361: 439-449.
34. Thoms JA, Birger Y, Foster S, Knezevic K, Kirschenbaum Y, Chandrakanthan V et al. ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer. Blood 2011; 117: 7079-7089.
35. Rivera RR, Stuiver MH, Steenbergen R, Murre C. ETS proteins: new factors that regulate immunoglobulin heavy-chain gene expression. Mol Cell Biol 1993; 13: 7163-7169.
36. Anderson MK, Hernandez-Hoyos G, Diamond RA, Rothenberg EV. Precise developmental regulation of ETS family transcription factors during specification and commitment to the T cell lineage. Development 1999; 126: 3131-3148.
37. Dhordain P, Dewitte F, Desbiens X, Stehelin D, Duterque-Coquillaud M. Mesodermal expression of the chicken ERG gene associated with precartilaginous condensation and cartilage differentiation. Mech Dev 1995; 50: 17-28.
38. Iwamoto M, Higuchi Y, Koyama E, Enomoto-Iwamoto M, Kurisu K, Yeh H et al. Transcription factor ERG variants and functional diversification of chondrocytes during limb long bone development. J Cell Biol 2000; 150: 27-40.
39. Cox MK, Appelboom BL, Ban GI, Serra R. ERG cooperates with TGF-β to control mesenchymal differentiation. Exp Cell Res 2014; 328: 410-418.
40. Iwamoto M, Ohta Y, Larmour C, Enomoto-Iwamoto M. Toward regeneration of articular cartilage. Birth Defects Res C Embryo Today Rev 2013; 99: 192-202.
41. Hagen RM, Adamo P, Karamat S, Oxley J, Aning JJ, Gillatt D et al. Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence. Am J Clin Pathol 2014; 142: 533-540.
42. Donaldson LW, Petersen JM, Graves BJ, McIntosh LP. Solution structure of the ETS domain from murine ETS-1: a winged helix-turn-helix DNA binding motif. EMBO J 1996; 15: 125.
43. Liang H, Mao X, Olejniczak ET, Nettesheim DG, Yu L, Meadows RP et al. Solution structure of the ets domain of Fli-1 when bound to DNA. Nat Struct Mol Biol 1994; 1: 871-876.
44. Werner MH, Marius Clore G, Fisher CL, Fisher RJ, Trinh L, Shiloach J et al. The solution structure of the human ETS1-DNA complex reveals a novel mode of binding and true side chain intercalation. Cell 1995; 83: 761-771.
45. Batchelor AH, Piper DE, de la Brousse FC, McKnight SL, Wolberger C. The structure of GABPα/β: an ETS domain-ankyrin repeat heterodimer bound to DNA. Science 1998; 279: 1037-1041.
46. Shore P, Whitmarsh AJ, Bhaskaran R, Davis RJ, Waltho JP, Sharrocks AD. Determinants of DNA-binding specificity of ETS-domain transcription factors. Mol Cell Biol 1996; 16: 3338-3349.
47. Wei GH, Badis G, Berger MF, Kivioja T, Palin K, Enge M et al. Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J 2010; 29: 2147-2160.
48. Shore P, Sharrocks AD. The ETS-domain transcription factors Elk-1 and SAP-1 exhibit differential DNA binding specifitoies. Nucleic Acids Res 1995; 23: 4698-4706.
49. Karim F, Urness L, Thummel C, Klemsz M, McKercher S, Celada A et al. The ETS-domain: a new DNA-binding motif that recognizes a purine-rich core DNA sequence. Genes Dev 1990; 4: 1451-1453.
50. Wang C, Petryniak B, Ho I-C, Thompson C, Leiden J. Evolutionarily conserved ETS family members display distinct DNA binding specificities. J Exp Med 1992; 175: 1391-1399.
51. Seth A, Ascione R, Fisher R, Mavrothalassitis G, Bhat N, Papas T. The ETS gene family. Cell Growth Differ 1992; 3: 327.
52. Prasad D, Rao V, Lee L, Reddy E. Differentially spliced ERG-3 product functions as a transcriptional activator. Oncogene 1994; 9: 669-673.
53. Anton IA, Frampton J. Tryptophans in myb proteins. Nature 1987; 336: 719-719.
54. Kanei-Ishii C, Sarai A, Sawazaki T, Nakagoshi H, He D-N, Ogata K et al. The tryptophan cluster: a hypothetical structure of the DNA-binding domain of the myb protooncogene product. J Biol Chem 1990; 265: 19990-19995.
55. Saikumar P, Murali R, Reddy EP. Role of tryptophan repeats and flanking amino acids in Myb-DNA interactions. Proc Natl Acad Sci 1990; 87: 8452-8456.
56. Basuyaux JP, Ferreira E, Stéhelin D, Butticè G. The Ets transcription factors interact with each other and with the c-Fos/c-Jun complex via distinct protein domains in a DNA-dependent and-independent manner. J Biol Chem 1997; 272: 26188-26195.
57. Salek-Ardakani S, Smooha G, de Boer J, Sebire NJ, Morrow M, Rainis L et al. ERG is a megakaryocytic oncogene. Cancer Research 2009; 69: 4665-4673.
58. Mackereth CD, Schärpf M, Gentile LN, MacIntosh SE, Slupsky CM, McIntosh LP. Diversity in structure and function of the Ets family PNT domains. J Mol Biol 2004; 342: 1249-1264.
59. Kim CA, Bowie JU. SAM domains: uniform structure, diversity of function. Trends Biochem Sci 2003; 28: 625-628.
60. Carrère S, Verger A, Flourens A, Stehelin D, Duterque-Coquillaud M. Erg proteins, transcription factors of the ETS family, form homo, heterodimers and ternary complexes via two distinct domains. Oncogene 1998; 16: 3261-3268.
61. Verger A, Buisine E, Carrère S, Wintjens R, Flourens A, Coll J et al. Identification of amino acid residues in the ETS transcription factor Erg that mediate Erg-Jun/Fos-DNA ternary complex formation. J Biol Chem 2001; 276: 17181-17189.
62. Lau DK, Okon M, McIntosh LP. The PNT domain from Drosophila pointed-P2 contains a dynamic N-terminal helix preceded by a disordered phosphoacceptor sequence. Protein Sci 2012; 21: 1716-1725.
63. Slupsky CM, Gentile LN, Donaldson LW, Mackereth CD, Seidel JJ, Graves BJ et al. Structure of the ETS-1 pointed domain and mitogen-activated protein kinase phosphorylation site. Proc Natl Acad Sci USA 1998; 95: 12129-12134.
64. Shwartz A, Yogev S, Schejter ED, Shilo B-Z. Sequential activation of ETS proteins provides a sustained transcriptional response to EGFR signaling. Development 2013; 140: 2746-2754.
65. Seidel JJ, Graves BJ. An ERK2 docking site in the pointed domain distinguishes a subset of ETS transcription factors. Genes Dev 2002; 16: 127-137.
66. Singareddy R, Semaan L, Conley-LaComb MK, John JS, Powell K, Iyer M et al. Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions. Mol Cancer Res 2013; 11: 1349-1361.
67. Siddique H, Rao V, Lee L, Reddy E. Characterization of the DNA binding and transcriptional activation domains of the ERG protein. Oncogene 1993; 8: 1751-1755.
68. Kim S, Denny CT, Wisdom R. Cooperative DNA binding with AP-1 proteins is required for transformation by EWS-Ets fusion proteins. Mol Cell Biol 2006; 26: 2467-2478.
69. Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, Vainio P et al. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 2010; 70: 6735-6745.
70. Regan MC, Horanyi PS, Pryor EE, Sarver JL, Cafiso DS, Bushweller JH. Structural and dynamic studies of the transcription factor ERG reveal DNA binding is allosterically autoinhibited. Proc Natl Acad Sci USA 2013; 110: 13374-13379.
71. Coyne HJ III, De S, Okon M, Green SM, Bhachech N, Graves BJ et al. Autoinhibition of ETV6 (TEL) DNA binding: appended helices sterically block the ETS domain. J Mol Biol 2012; 421: 67-84.
72. Green SM, Coyne HJ, McIntosh LP, Graves BJ. DNA binding by the ETS protein TEL (ETV6) is regulated by autoinhibition and self-association. J Biol Chem 2010; 285: 18496-18504.
73. Jolma A, Kivioja T, Toivonen J, Cheng L, Wei G, Enge M et al. Multiplexed massively parallel SELEX for characterization of human transcription factor binding specificities. Genome Res 2010; 20: 861-873.
74. Nye JA, Petersen JM, Gunther CV, Jonsen MD, Graves BJ. Interaction of murine ETS-1 with GGA-binding sites establishes the ETS domain as a new DNA-binding motif. Genes Dev 1992; 6: 975-990.
75. Oikawa T, Yamada T. Molecular biology of the ETS family of transcription factors. Gene 2003; 303: 11-34.
76. Hollenhorst PC, Shah AA, Hopkins C, Graves BJ. Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. Genes Dev 2007; 21: 1882-1894.
77. Sementchenko VI, Watson DK. ETS target genes: past, present and future. Oncogene 2000; 19: 6533-6548.
78. Camuzeaux B, Spriet C, Héliot L, Coll J, Duterque-Coquillaud M. Imaging ERG and Jun transcription factor interaction in living cells using fluorescence resonance energy transfer analyses. Biochem Biophys Res Commun 2005; 332: 1107-1114.
79. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun X-W et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648.
80. Wang J, Cai Y, Yu W, Ren C, Spencer DM, Ittmann M. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res 2008; 68: 8516-8524.
81. Owczarek C, Portbury K, Hardy M, O'Leary D, Kudoh J, Shibuya K et al. Detailed mapping of the ERG- ETS2 interval of human chromosome 21 and comparison with the region of conserved synteny on mouse chromosome 16. Gene 2004; 324: 65-77.
82. Duterque-Coquillaud M, Niel C, Plaza S, Stehelin D. New human erg isoforms generated by alternative splicing are transcriptional activators. Oncogene 1993; 8: 1865-1873.
83. Zammarchi F, Boutsalis G, Cartegni L. 5′ UTR control of native ERG and of Tmprss2: ERG variants activity in prostate cancer. PloS One 2013; 8: e49721.
84. Rainis L, Toki T, Pimanda JE, Rosenthal E, Machol K, Strehl S et al. The protooncogene ERG in megakaryoblastic leukemias. Cancer Res 2005; 65: 7596-7602.
85. Schwartzman J, Mongoue-Tchokote S, Gibbs A, Gao L, Corless CL, Jin J et al. A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer. Epigenetics 2011; 6: 1248-1256.
86. Bohne A, Schlee C, Mossner M, Thibaut J, Heesch S, Thiel E et al. Epigenetic control of differential expression of specific ERG isoforms in acute T-lymphoblastic leukemia. Leukemia Res 2009; 33: 817-822.
87. Mani R-S, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009; 326: 1230-1230.
88. Mani R-S, Iyer MK, Cao Q, Brenner JC, Wang L, Ghosh A et al. TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers. Cancer Res 2011; 71: 5387-5392.
89. Deramaudt TB, Remy P, Stiegler P. Identification of interaction partners for two closely-related members of the ETS protein family, FLI and ERG. Gene 2001; 274: 169-177.
90. Iwamoto M, Tamamura Y, Koyama E, Komori T, Takeshita N, Williams JA et al. Transcription factor ERG and joint and articular cartilage formation during mouse limb and spine skeletogenesis. Dev Biol 2007; 305: 40-51.
91. Vanaja DK, Cheville JC, Iturria SJ, Young CY. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 2003; 63: 3877-3882.
92. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008; 10: 177-IN179.
93. Carver BS, Tran J, Chen Z, Carracedo-Perez A, Alimonti A, Nardella C et al. ETS rearrangements and prostate cancer initiation. Nature 2009; 457: E1-E1.
94. Hägglöf C, Hammarsten P, Strömvall K, Egevad L, Josefsson A, Stattin P et al. TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers. PloS One 2014; 9: e86824.
95. Baldus CD, Burmeister T, Martus P, Schwartz S, Gökbuget N, Bloomfield CD et al. High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. J Clin Oncol 2006; 24: 4714-4720.
96. Shimizu K, Ichikawa H, Tojo A, Kaneko Y, Maseki N, Hayashi Y et al. An ETS-related gene, ERG, is rearranged in human myeloid leukemia with t (16; 21) chromosomal translocation. Proc Natl Acad Sci USA 1993; 90: 10280-10284.
97. Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA, Witte ON. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci 2009; 106: 12465-12470.
98. Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R et al. TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PloS One 2011; 6: e21650.
99. Brase JC, Johannes M, Mannsperger H, Fälth M, Metzger J, Kacprzyk LA et al. TMPRSS2-ERG-specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling. BMC Cancer 2011; 11: 507.
100. Becker-Santos DD, Guo Y, Ghaffari M, Vickers ED, Lehman M, Altamirano-Dimas M et al. Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models. Carcinogenesis 2012; 33: 2558-2567.
101. Zhang X, Fournier MV, Ware JL, Bissell MJ, Yacoub A, Zehner ZE. Inhibition of vimentin or β1 integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo. Mol Cancer Ther 2009; 8: 499-508.
102. Wu L, Zhao JC, Kim J, Jin H-J, Wang C-Y, Yu J. ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer. Cancer Res 2013; 73: 6068-6079.
103. Butticè G, Duterque-Coquillaud M, Basuyaux J-P, Carrere S, Kurkinen M, Stéhelin D. ERG, an ETS-family member, differentially regulates human collagenase1 (MMP1) and stromelysin1 (MMP3) gene expression by physically interacting with the Fos/Jun complex. Oncogene 1996; 13: 2297-2306.
104. Sun C, Dobi A, Mohamed A, Li H, Thangapazham R, Furusato B et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 2008; 27: 5348-5353.
105. Cai J, Kandagatla P, Singareddy R, Kropinski A, Sheng S, Cher ML et al. Androgens induce functional CXCR4 through ERG factor expression in TMPRSS2-ERG fusion-positive prostate cancer cells. Transl Oncol 2010; 3: 195-IN191.
106. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62: 1832-1837.
107. Rocks N, Paulissen G, El Hour M, Quesada F, Crahay C, Gueders M et al. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie 2008; 90: 369-379.
108. Furusato B, Tan S, Young D, Dobi A, Sun C, Mohamed A et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 2010; 13: 228-237.
109. Casey OM, Fang L, Hynes PG, Abou-Kheir WG, Martin PL, Tillman HS et al. TMPRSS2-driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation. PloS One 2012; 7: e41668.
110. Lawson DA, Zong Y, Memarzadeh S, Xin L, Huang J, Witte ON. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci 2010; 107: 2610-2615.
111. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identification of a cell of origin for human prostate cancer. Science 2010; 329: 568-571.
112. Yu J, Yu J, Mani R-S, Cao Q, Brenner CJ, Cao X et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010; 17: 443-454.
113. Chng KR, Chang CW, Tan SK, Yang C, Hong SZ, Sng NYW et al. A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. EMBO Jl 2012; 31: 2810-2823.
114. Wright ME, Tsai M-J, Aebersold R. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 2003; 17: 1726-1737.
115. Rickman DS, Chen Y-b, Banerjee S, Pan Y, Yu J, Vuong T et al. ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia 2010; 12: 1031-IN1022.
116. Bernard D, Pourtier-Manzanedo A, Gil J, Beach DH. Myc confers androgen-independent prostate cancer cell growth. J Clin Invest 2003; 112: 1724-1731.
117. Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn I, McLeod D et al. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer Prostatic Dis 2010; 13: 311-315.
118. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004; 4: 793-805.
119. Fortson WS, Kayarthodi S, Fujimura Y, Xu H, Matthews R, Grizzle WE et al. Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells. Int J Oncol 2011; 39: 111.
120. Yang L, Xia L, Wu DY, Wang H, Chansky HA, Schubach WH et al. Molecular cloning of ESET, a novel histone H3-specific methyltransferase that interacts with ERG transcription factor. Oncogene 2002; 21: 148-152.
121. Yang L, Mei Q, Zielinska-Kwiatkowska A, Matsui Y, Blackburn M, Benedetti D et al. An ERG (ETS-related gene)-associated histone methyltransferase interacts with histone deacetylases 1/2 and transcription co-repressors mSin3A/B. Biochem J 2003; 369: 651-657.
122. Yeap L-S, Hayashi K, Surani MA. ERG-associated protein with SET domain (ESET)-Oct4 interaction regulates pluripotency and represses the trophectoderm lineage. Epigenet Chromatin 2009; 2: 12.
123. Yuan P, Han J, Guo G, Orlov YL, Huss M, Loh Y-H et al. Eset partners with Oct4 to restrict extraembryonic trophoblast lineage potential in embryonic stem cells. Genes Dev 2009; 23: 2507-2520.
124. Gordanpour A, Stanimirovic A, Nam RK, Moreno CS, Sherman C, Sugar L et al. miR-221 Is down-regulated in TMPRSS2: ERG fusion-positive prostate cancer. Anticancer Res 2011; 31: 403-410.
125. Xiao J, Gong AY, Eischeid AN, Chen D, Deng C, Young CY et al. miR-141 modulates androgen receptor transcriptional activity in human prostate cancer cells through targeting the small heterodimer partner protein. Prostate 2012; 72: 1514-1522.
126. Kim J, Wu L, Zhao J, Jin H, Yu J. TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c. Oncogene 2014; 33: 5183-5192.
127. Hart M, Wach S, Nolte E, Szczyrba J, Menon R, Taubert H et al. The protooncogene ERG is a target of microRNA miR-145 in prostate cancer. FEBS J 2013; 280: 2105-2116.
128. Kao C, Martiniez A, Shi X, Yang J, Evans C, Dobi A et al. miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene 2014; 33: 2495-2503.
129. Dunn T, Praissman L, Hagag N, Viola MV. ERG gene is translocated in an Ewing's sarcoma cell line. Cancer Genet Cytogenet 1994; 76: 19-22.
130. Tsuzuki S, Taguchi O, Seto M. Promotion and maintenance of leukemia by ERG. Blood 2011; 117: 3858-3868.
131. Sorensen PH, Lessnickz SL, Lopez-Terrada D, Liu XF. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994; 6: 146-151.
132. Ichikawa H, Shimizu K, Hayashi Y, Ohki M. An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t (16; 21) chromosomal translocation. Cancer Res 1994; 54: 2865-2868.
133. Panagopoulos I, Åman P, Fioretos T, Höglund M, Johansson B, Mandahl N et al. Fusion of the FUS gene with ERG in acute myeloid leukemia with t (16; 21) (p11; q22). Genes Chromosomes Cancer 1994; 11: 256-262.
134. Hart AH, Corrick CM, Tymms MJ, Hertzog PJ, Kola I. Human ERG is a protooncogene with mitogenic and transforming activity. Oncogene 1995; 10: 1423-1430.
135. Paoloni-Giacobino A, Chen H, Peitsch MC, Rossier C, Antonarakis SE. Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22. 3. Genomics 1997; 44: 309-320.
136. Lin B, Ferguson C, White JT, Wang S, Vessella R, True LD et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 1999; 59: 4180-4184.
137. Chen Y-W, Lee M-S, Lucht A, Chou F-P, Huang W, Havighurst TC et al. TMPRSS2, a serine protease expressed in the prostate on the apical surface of luminal epithelial cells and released into semen in prostasomes, is misregulated in prostate cancer cells. Am J Pathol 2010; 176: 2986-2996.
138. Donaldson SH, Hirsh A, Li DC, Holloway G, Chao J, Boucher RC et al. Regulation of the epithelial sodium channel by serine proteases in human airways. Journal of Biological Chemistry 2002; 277: 8338-8345.
139. Böttcher-Friebertshäuser E, Freuer C, Sielaff F, Schmidt S, Eickmann M, Uhlendorff J et al. Cleavage of influenza virus hemagglutinin by airway proteases TMPRSS2 and HAT differs in subcellular localization and susceptibility to protease inhibitors. J Virol 2010; 84: 5605-5614.
140. Bertram S, Glowacka I, Blazejewska P, Soilleux E, Allen P, Danisch S et al. TMPRSS2 and TMPRSS4 facilitate trypsin-independent spread of influenza virus in Caco-2 cells. J Virol 2010; 84: 10016-10025.
141. Hatesuer B, Bertram S, Mehnert N, Bahgat MM, Nelson PS, Pöhlman S et al. Tmprss2 is essential for influenza H1N1 virus pathogenesis in mice. PLoS Pathogens 2013; 9: e1003774.
142. Bertram S, Heurich A, Lavender H, Gierer S, Danisch S, Perin P et al. Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts. PloS One 2012; 7: e35876.
143. Glowacka I, Bertram S, Müller MA, Allen P, Soilleux E, Pfefferle S et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol 2011; 85: 4122-4134.
144. Wilson S, Greer B, Hooper J, Zijlstra A, Walker B, Quigley J et al. The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells. Biochem J 2005; 388: 967-972.
145. Kim TS, Heinlein C, Hackman RC, Nelson PS. Phenotypic analysis of mice lacking the TMPRSS2-encoded protease. Mol Cell Biol 2006; 26: 965-975.
146. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera J-M, Setlur S et al. TMPRSS2: ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006; 66: 8337-8341.
147. Rubin MA, Chinnaiyan AM. Bioinformatics approach leads to the discovery of the TMPRSS2: ETS gene fusion in prostate cancer. Lab Invest 2006; 86: 1099-1102.
148. Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 2006; 66: 10242-10246.
149. Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden WM, Trapman J. TMPRSS2: ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 2006; 66: 10658-10663.
150. Liu W, Ewing CM, Chang BL, Li T, Sun J, Turner AR et al. Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers. Genes Chromosomes Cancer 2007; 46: 972-980.
151. Wu D, Zhang C, Shen Y, Nephew KP, Wang Q. Androgen receptor-driven chromatin looping in prostate cancer. Trends Endocrinol Metab 2011; 22: 474-480.
152. Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 2010; 42: 668-675.
153. Bastus NC, Boyd LK, Mao X, Stankiewicz E, Kudahetti SC, Oliver RTD et al. Androgen-induced TMPRSS2: ERG fusion in nonmalignant prostate epithelial cells. Cancer Res 2010; 70: 9544-9548.
154. Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. J Clin Oncol 2011; 29: 3659-3668.
155. Rickman DS, Soong TD, Moss B, Mosquera JM, Dlabal J, Terry S et al. Oncogene-mediated alterations in chromatin conformation. Proc Natl Acad Sci USA 2012; 109: 9083-9088.
156. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA et al. Mechanistic rationale for inhibition of poly (ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011; 19: 664-678.
157. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470: 214-220.
158. Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008; 68: 3584-3590.
159. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2006; 39: 41-51.
160. Soller W, Johansson Soller M, Isaksson M, Elfving P, Abrahamsson P, Lundgren R et al. High frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Eur Urol Suppl 2006; 5: 789.
161. Winnes M, Lissbrant E, Damber J-E, Stenman G. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep 2007; 17: 1033-1036.
162. Clark J, Attard G, Jhavar S, Flohr P, Reid A, De-Bono J et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 2007; 27: 1993-2003.
163. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006; 66: 8347-8351.
164. Hu Y, Dobi A, Sreenath T, Cook C, Tadase AY, Ravindranath L et al. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res 2008; 14: 4719-4725.
165. Furusato B, Gao C-L, Ravindranath L, Chen Y, Cullen J, McLeod DG et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 2007; 21: 67-75.
166. Zhang S, Pavlovitz B, Tull J, Wang Y, Deng F-M, Fuller C. Detection of TMPRSS2 gene deletions and translocations in carcinoma, intraepithelial neoplasia, and normal epithelium of the prostate by direct fluorescence in situ hybridization. Diagn Mol Pathol 2010; 19: 151-156.
167. Mosquera J-M, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 2008; 14: 3380-3385.
168. Cerveira N, Ribeiro FR, Peixoto A, Costa V, Henrique R, Jerönimo C et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas, paired HGPIN lesions. Neoplasia 2006; 8: 826-832.
169. Nam R, Sugar L, Yang W, Srivastava S, Klotz L, Yang L et al. Expression of the TMPRSS2: ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007; 97: 1690-1695.
170. Lapointe J, Kim YH, Miller MA, Li C, Kaygusuz G, van de Rijn M et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol 2007; 20: 467-473.
171. Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007; 20: 538-544.
172. Demichelis F, Fall K, Perner S, Andrén O, Schmidt F, Setlur S et al. TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007; 26: 4596-4599.
173. Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res 2007; 67: 7991-7995
174. Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A et al. Frequency of the TMPRSS2: ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007; 60: 1238-1243.
175. Dai M, Chen L, Zheng Y, Chen W, Tao Z, Weng Z et al. Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer. Zhonghua Yi Xue Za Zhi 2008; 88: 669-673.
176. Rouzier C, Haudebourg J, Carpentier X, Valério L, Amiel J, Michiels J-F et al. Detection of the TMPRSS2- ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data. Cancer Genet Cytogenet 2008; 183: 21-27.
177. Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009; 69: 1400-1406.
178. Robert G, Jannink S, Smit F, Aalders T, Hessels D, Cremers R et al. Rational basis for the combination of PCA3 and TMPRSS2: ERG gene fusion for prostate cancer diagnosis. Prostate 2013; 73: 113-120.
179. Velaeti S, Dimitriadis E, Kontogianni-Katsarou K, Savvani A, Sdrolia E, Pantazi G et al. Detection of TMPRSS2-ERG fusion gene in benign prostatic hyperplasia. Tumour Biol 2014; 35: 9597-9602.
180. Huang K-C, Dolph M, Donnelly B, Bismar T. ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer. Clin Transl Oncol 2014; 16: 1-7.
181. Petrovics G, Liu A, Shaheduzzaman S, Furasato B, Sun C, Chen Y et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005; 24: 3847-3852.
182. Saramäki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T. TMPRSS2: ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 2008; 14: 3395-3400.
183. Hermans KG, Boormans JL, Gasi D, van Leenders GJ, Jenster G, Verhagen PC et al. Overexpression of prostate-specific TMPRSS2 (exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res 2009; 15: 6398-6403.
184. Fine SW, Gopalan A, Leversha MA, Al-Ahmadie HA, Tickoo SK, Zhou Q et al. TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol 2010; 23: 1325-1333.
185. Tian T, Tomavo N, Huot L, Flourens A, Bonnelye E, Flajollet S et al. Identification of novel TMPRSS2: ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2. Oncogene 2014; 33: 2204-2214.
186. Tsourlakis MC, Weigand P, Grupp K, Kluth M, Steurer S, Schlomm T et al. βIII-Tubulin overexpression iI an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion. Am J Pathol 2014; 184: 609-617.
187. Sreenath TL, Dobi A, Petrovics G, Srivastava S. Oncogenic activation of ERG: a predominant mechanism in prostate cancer. J Carcinogenesis 2011; 10: 37.
188. Abate-Shen C, Shen MM, Gelman E. Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation 2008; 76: 717-727.
189. Thangapazham R, Saenz F, Katta S, Mohamed AA, Tan S-H, Petrovics G et al. Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer. BMC Cancer 2014; 14: 16.
190. Berezovska OP, Glinskii AB, Yang Z, Li X-M, Hoffman RM, Glinsky GV. Report essential role for activation of the polycomb-group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 2006; 5: 1886-1901.
191. Lee W-H, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci 1994; 91: 11733-11737.
192. Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008; 100: 815-825.
193. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat J-P et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012; 44: 685-689.
194. Grasso CS, Wu Y-M, Robinson DR, Cao X, Dhanasekaran SM, Khan AP et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239-243.
195. Bowen KA, Doan HQ, Zhou BP, Wang Q, Zhou Y, Rychahou PG et al. PTEN loss induces epithelial - mesenchymal transition in human colon cancer cells. Anticancer Res 2009; 29: 4439-4449.
196. Netto GJ. TMPRSS2-ERG fusion as a marker of prostatic lineage in small-cell carcinoma. Histopathology 2010; 57: 633-633.
197. Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC et al. The TMPRSS2: ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prevent 2012; 21: 1497-1509.
198. Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE et al. Noninvasive detection of TMPRSS2: ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006; 8: 885-888.
199. Chatterjee P, Choudhary GS, Sharma A, Singh K, Heston WD, Ciezki J et al. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS One 2013; 8: e60408.
200. Björkman M, Iljin K, Halonen P, Sara H, Kaivanto E, Nees M et al. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. Int J Cancer 2008; 123: 2774-2781.
201. Rahim S, Beauchamp EM, Kong Y, Brown ML, Toretsky JA, Üren A. YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. PloS One 2011; 6: e19343.
202. Nhili R, Peixoto P, Depauw S, Flajollet S, Dezitter X, Munde MM et al. Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidines. Nucleic Acids Res 2013; 41: 125-138.
203. Wang S, Kollipara RK, Srivastava N, Li R, Ravindranathan P, Hernandez E et al. Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. Proc Natl Acad Sci 2014; 111: 4251-4256.
204. Shao L, Tekedereli I, Wang J, Yuca E, Tsang S, Sood A et al. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res 2012; 18: 6648-6657.
205. Leinonen KA, Saramäki OR, Furusato B, Kimura T, Takahashi H, Egawa S et al. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prevent 2013; 22: 2333-2344.